Dapagliflozin
Treatment for Chronic kidney disease due to diabetes mellitus type 1
Typical Dosage: 10mg once daily
Effectiveness
88%
Safety Score
65%
Clinical Trials
1
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
10mg once daily
Time to Effect
Months to years for renal/CV protection, weeks for glycemic/BP effects
Treatment Duration
Lifetime
Evidence Quality
MODERATENumber Needed to Treat (NNT)
20(Treat 20 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
30(Treat 30 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,500
Monitoring:$300
Side Effect Mgmt:$300
Total Annual:$6,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
0.6
Outcome-Based Costs
Cost per Responder
$8,133
Dapagliflozin Outcomes
for Chronic kidney disease due to diabetes mellitus type 1
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+75%
Common Side Effects
Genital mycotic infections
+12%
Urinary tract infections
+8%
Hypotension
+4%
Euglycemic diabetic ketoacidosis (T1DM)
+3%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
1 completed trial for Dapagliflozin in Chronic kidney disease due to diabetes mellitus type 1
Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.
NCT06374043COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Almelo, Netherlands +1 more
Started: May 11, 2021